125 related articles for article (PubMed ID: 38497158)
61. Low-risk HPLLs/ABC score patients with splenic marginal zone lymphoma can be safely managed without treatment: Results from a prospective Spanish study.
Muntañola A; Villalobos MT; González-Villambrosia S; Rodríguez-Salazar MJ; Jiménez-Ubieto A; Bastidas-Mora G; Córdoba R; Infante M; Vidal MJ; Díaz FJ; Baile M; Bastos-Oreiro M; Panizo C; Sancho JM; Navarro B; García T; Escoda L; Abrisqueta P; Terol MJ; de Campo R; Mozas P; López-Guillermo A; Salar A; Montalbán C;
Br J Haematol; 2023 Aug; 202(4):776-784. PubMed ID: 37386877
[TBL] [Abstract][Full Text] [Related]
62. Splenic marginal zone lymphoma: Prognostic factors, role of watch and wait policy, and other therapeutic approaches in the rituximab era.
Perrone S; D'Elia GM; Annechini G; Ferretti A; Tosti ME; Foà R; Pulsoni A
Leuk Res; 2016 May; 44():53-60. PubMed ID: 27030961
[TBL] [Abstract][Full Text] [Related]
63. Bendamustine, bortezomib and rituximab produces durable complete remissions in patients with previously untreated, low grade lymphoma.
Flinn IW; Thompson DS; Boccia RV; Miletello G; Lipman A; Flora D; Cuevas D; Papish SW; Berdeja JG
Br J Haematol; 2018 Feb; 180(3):365-373. PubMed ID: 29193021
[TBL] [Abstract][Full Text] [Related]
64. Carfilzomib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma: A Phase I Trial.
Kambhampati S; Fakhri B; Ai WZ; Kaplan LD; Tuscano JM; Wieduwilt MJ; Sudhindra A; Cavallone E; Reiner J; Aoun C; Castillo M; Martinelli M; Ta T; Le D; Padilla M; Crawford E; Andreadis CB
Clin Lymphoma Myeloma Leuk; 2021 Mar; 21(3):139-146. PubMed ID: 33478921
[TBL] [Abstract][Full Text] [Related]
65. Long-term efficacy and toxicity of rituximab plus fludarabine and mitoxantrone (R-FM) for gastric marginal zone lymphoma: a single-center experience and literature review.
Cencini E; Fabbri A; Lauria F; Bocchia M
Ann Hematol; 2018 May; 97(5):821-829. PubMed ID: 29340761
[TBL] [Abstract][Full Text] [Related]
66. Bendamustine plus rituximab versus fludarabine plus rituximab for patients with relapsed indolent and mantle-cell lymphomas: a multicentre, randomised, open-label, non-inferiority phase 3 trial.
Rummel M; Kaiser U; Balser C; Stauch M; Brugger W; Welslau M; Niederle N; Losem C; Boeck HP; Weidmann E; von Gruenhagen U; Mueller L; Sandherr M; Hahn L; Vereshchagina J; Kauff F; Blau W; Hinke A; Barth J;
Lancet Oncol; 2016 Jan; 17(1):57-66. PubMed ID: 26655425
[TBL] [Abstract][Full Text] [Related]
67. Bendamustine plus rituximab for previously untreated patients with indolent B-cell non-Hodgkin lymphoma or mantle cell lymphoma: a multicenter Phase II clinical trial in Japan.
Ogura M; Ishizawa K; Maruyama D; Uike N; Ando K; Izutsu K; Terui Y; Imaizumi Y; Tsukasaki K; Suzuki K; Izumi T; Usuki K; Kinoshita T; Taniwaki M; Uoshima N; Suzumiya J; Kurosawa M; Nagai H; Uchida T; Fukuhara N; Choi I; Ohmachi K; Yamamoto G; Tobinai K;
Int J Hematol; 2017 Apr; 105(4):470-477. PubMed ID: 27900638
[TBL] [Abstract][Full Text] [Related]
68. Treatment of splenic marginal zone lymphoma with rituximab monotherapy: progress report and comparison with splenectomy.
Kalpadakis C; Pangalis GA; Angelopoulou MK; Sachanas S; Kontopidou FN; Yiakoumis X; Kokoris SI; Dimitriadou EM; Dimopoulou MN; Moschogiannis M; Korkolopoulou P; Kyrtsonis MC; Siakantaris MP; Papadaki T; Tsaftaridis P; Plata E; Papadaki HE; Vassilakopoulos TP
Oncologist; 2013; 18(2):190-7. PubMed ID: 23345547
[TBL] [Abstract][Full Text] [Related]
69. Effectiveness of Bendamustine-Rituximab Compared to R-CHOP/R-CVP as a First-Line Treatment of Indolent Non-Hodgkin's Lymphoma or Mantle-Cell Lymphoma.
Edina BC; Rinaldi I
Acta Med Indones; 2022 Apr; 54(2):316-323. PubMed ID: 35818660
[TBL] [Abstract][Full Text] [Related]
70. Bendamustine-120 plus rituximab therapy for relapsed or refractory follicular lymphoma: a multicenter phase II study.
Sakai R; Ohmachi K; Sano F; Watanabe R; Takahashi H; Takasaki H; Tanaka M; Hattori Y; Kimura H; Takimoto M; Tachibana T; Tanaka E; Ishii Y; Ishiyama Y; Hagihara M; Miyazaki K; Yamamoto K; Tomita N; Ando K
Ann Hematol; 2019 Sep; 98(9):2131-2138. PubMed ID: 31286196
[TBL] [Abstract][Full Text] [Related]
71. [Splenic marginal zone lymphoma complicated by cold agglutinin disease].
Ochi K; Yokoyama K; Ohno N; Ota Y; Tojo A
Rinsho Ketsueki; 2017; 58(2):132-137. PubMed ID: 28321090
[TBL] [Abstract][Full Text] [Related]
72. Successful Treatment of Leukemic Mature B-Cell Lymphoid Neoplasm with Similar Features to Splenic Marginal Zone Lymphoma Possessing Aberrant Myeloid Markers.
Imashuku S; Kudo N; Kubo K; Saigo K
Case Rep Hematol; 2015; 2015():181263. PubMed ID: 26558117
[TBL] [Abstract][Full Text] [Related]
73. Efficacy and safety of rituximab plus bendamustine for gastric marginal zone lymphoma.
Cencini E; Fabbri A; Schiattone L; Bocchia M
Leuk Lymphoma; 2019 Mar; 60(3):833-835. PubMed ID: 30234387
[No Abstract] [Full Text] [Related]
74. Bendamustine in chronic lymphocytic leukemia and refractory lymphoma.
Rummel MJ
Semin Hematol; 2008 Jul; 45(3 Suppl 2):S7-10. PubMed ID: 18760709
[TBL] [Abstract][Full Text] [Related]
75. Combination of rituximab, cyclophosphamide, and vincristine induces complete hematologic remission of splenic marginal zone lymphoma.
Arcaini L; Orlandi E; Scotti M; Brusamolino E; Passamonti F; Burcheri S; Colombo N; Vanelli L; Sbalzarini G; Lazzarino M
Clin Lymphoma; 2004 Mar; 4(4):250-2. PubMed ID: 15072617
[TBL] [Abstract][Full Text] [Related]
76. A brief rituximab, bendamustine, mitoxantrone (R-BM) induction followed by rituximab consolidation in elderly patients with advanced follicular lymphoma: a phase II study by the Fondazione Italiana Linfomi (FIL).
Boccomini C; Ladetto M; Rigacci L; Puccini B; Rattotti S; Volpetti S; Ferrero S; Chiarenza A; Freilone R; Novo M; Corradini P; Nassi L; Rusconi C; Stelitano C; Bolis S; Marina Liberati A; Tucci A; Baldini L; Balzarotti M; Evangelista A; Ciccone G; Vitolo U
Br J Haematol; 2021 Apr; 193(2):280-289. PubMed ID: 33476434
[TBL] [Abstract][Full Text] [Related]
77. Rituximab for treatment of advanced extranodal marginal zone B cell lymphoma of the mucosa-associated lymphoid tissue lymphoma.
Raderer M; Jäger G; Brugger S; Püspök A; Fiebiger W; Drach J; Wotherspoon A; Chott A
Oncology; 2003; 65(4):306-10. PubMed ID: 14707449
[TBL] [Abstract][Full Text] [Related]
78. Rare lymphomas in routine practice - Treatment and outcome in marginal zone lymphoma in the prospective German Tumour Registry Lymphatic Neoplasms.
Knauf W; Abenhardt W; Koenigsmann M; Maintz C; Sandner R; Zahn MO; Schnell R; Tech S; Kaiser-Osterhues A; Houet L; Marschner N;
Hematol Oncol; 2021 Aug; 39(3):313-325. PubMed ID: 33942348
[TBL] [Abstract][Full Text] [Related]
79. Rituximab monotherapy is highly effective in splenic marginal zone lymphoma.
Kalpadakis C; Pangalis GA; Dimopoulou MN; Vassilakopoulos TP; Kyrtsonis MC; Korkolopoulou P; Kontopidou FN; Siakantaris MP; Dimitriadou EM; Kokoris SI; Tsaftaridis P; Plata E; Angelopoulou MK
Hematol Oncol; 2007 Sep; 25(3):127-31. PubMed ID: 17514771
[TBL] [Abstract][Full Text] [Related]
80. Rare presentation of secondary cutaneous involvement by splenic marginal zone lymphoma: report of a case and review of the literature.
Cohen JM; Nazarian RM; Ferry JA; Takvorian RW; Carter JB
Am J Dermatopathol; 2015 Jan; 37(1):e1-4. PubMed ID: 25238446
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
